Natco Pharma Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug (RLD), Lynparza Tablets, marketed by AstraZeneca Pharmaceuticals, for the indications specified in the approved labelling.

Under the partnership arrangement, NATCO Pharma will manufacture the Olaparib tablets, while Alembic Pharmaceuticals will distribute the product in the United States.

Olaparib, marketed under the brand name Lynparza, is a targeted cancer therapy belonging to the class of PARP inhibitors. It is indicated for the treatment of certain types of ovarian, breast, pancreatic and prostate cancers by preventing cancer cells with specific genetic mutations, such as BRCA or HRR mutations, from repairing damaged DNA.

The company said the Paragraph IV (Para IV) patent litigation related to the product is ongoing. According to industry sales data, Olaparib tablets recorded estimated U.S. sales of approximately USD 1.4 billion for the 12 months ended March 2026.

NATCO Pharma, headquartered in Hyderabad, develops, manufactures and markets generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients (APIs) and crop protection products.

The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore in the corresponding quarter last year. Revenue from operations declined 39.46% YoY to Rs 739.1 crore during the quarter ended 31 March 2026.

Powered by Capital Market - Live News

Natco Pharma announced the successful completion of its acquisition of an additional 13.25% equity stake in Adcock Ingram Holdings Proprietary Limited (Adcock Ingram), a leading South African pharmaceutical and healthcare company.

With the completion of this transaction, NATCO's shareholding in Adcock Ingram has increased from 35.75% to 49%. The acquisition was completed through NATCO Pharma South Africa Proprietary, NATCO's wholly owned subsidiary in South Africa.

The transaction involved the acquisition of shares for an aggregate consideration of around ZAR 1.81 billion equivalent to around Rs 1,060 crore at the transaction exchange rate.

NATCO first acquired 35.75% in Adcock Ingram through its participation in the Adcock Ingram's delisting process in 2025 following the announcement of a firm intention offer in July 2025, shareholder approval in October 2025 and completion of the transaction in November 2025.

The approved product is bioequivalent to Halaven Injection, the reference-listed drug (RLD) marketed by Eisai Inc.

Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously undergone at least two chemotherapy regimens for metastatic disease. It is also used for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

According to IQVIA MAT data for April 2026, the reference drug Halaven recorded estimated annual sales of approximately $43.7 million in the United States.

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore posted in the corresponding quarter last year. Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026. The counter slipped 2.48% to Rs 915.80 on the BSE.

Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company?s consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25 and higher by 24.42% from Rs 1,180.50 crore in Q3 FY26. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. It increased 4.1% sequentially from Rs 7100.5 crore in Q3 FY26. The counter shed 0.20% to Rs 2,245.10 on the BSE.

Powered by Capital Market - Live News

Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026.

Profit before tax (PBT) declined sharply by 71.51% to Rs 144.1 crore in Q4 FY26 from Rs 505.9 crore recorded in Q4 FY25.

On the segmental front, revenue from the pharmaceuticals business stood at Rs 716.5 crore, down 40.58% year-on-year. Meanwhile, revenue from the agro chemicals segment increased 50.66% YoY to Rs 716.5 crore in Q4 FY26.

For the full financial year FY26, Natco Pharma reported a 24.76% decline in consolidated net profit to Rs 1,418.5 crore. Revenue from operations decreased 7.92% year-on-year to Rs 4,078.3 crore in FY26.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

Powered by Capital Market - Live News